Traws Pharma (TRAW) Accumulated Expenses (2012 - 2026)

Traws Pharma (TRAW) has reported Accumulated Expenses for 15 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 837.9% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $5.5 million (up 837.9% YoY), while the FY2025 annual figure was $5.5 million, up 1972.83% from the prior year.
• Accumulated Expenses rose to $5.5 million in Q1 2026 per TRAW's latest filing, from $5.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $5.5 million in Q1 2026 and bottomed at $192000.0 in Q2 2025.
• Historically, Accumulated Expenses has averaged $2.4 million across 5 years, with a median of $2.6 million in 2022.
• On a YoY basis, Accumulated Expenses climbed as much as 1972.83% in 2025 and fell as far as 94.53% in 2025.
• Traws Pharma's Accumulated Expenses stood at $2.6 million in 2022, then surged by 30.16% to $3.4 million in 2023, then slumped by 92.15% to $265000.0 in 2024, then soared by 1972.83% to $5.5 million in 2025, then rose by 0.91% to $5.5 million in 2026.
• Business Quant data shows TRAW's Accumulated Expenses at $5.5 million in Q1 2026, $5.5 million in Q4 2025, and $774000.0 in Q3 2025.